Europäische Akademie Berlin
8. Energiesteuertag - 14./15. Dezember 2017: "Aktuelle Entwicklungen im Energie- und Stromsteuerrecht "Hörsaal 207 der Universität Salzburg, (Zugang beschildert)
Vorträge der Salzburger Juristischen Gesellschaft - Thema: "DATENSCHUTZ-AUDIT – Ab 25.05.2018 gilt die DSGVO - sind Sie vorbereitet?"
Stadtname / PLZ
Mo, 19.06.2017 11:05
pts20170619018 Medizin/Wellness, Produkte/Innovationen
AOP Orphan and Amomed Pharma announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria
Vienna (pts018/19.06.2017/11:05) - AOP Orphan Pharmaceuticals AG and Amomed Pharma GmbH announce the launch of RAPIBLOC® (Landiolol) in Germany and Austria.
AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that RAPIBLOC® (Rapibloc, 300 mg powder for solution for infusion) will as of June 19th be first commercialized by its distribution partner Amomed Pharma GmbH (Amomed) and thereby be available to treat patients in Germany and Austria followed by selected Central European countries. Later this year the product will furthermore be launched in Scandinavia. Launch preparations in other European countries are ongoing.
AOP Orphan and its partner, Amomed, have negotiated a commercialization agreement in April 2016 whereby Amomed´s regional subsidiaries in the EU will exclusively commercialize RAPIBLOC®. Amomed has also been granted distribution rights in selected regions outside the EU, with exception of USA and Canada.
"We are very pleased to have gained Amomed as an exclusive distribution partner for RAPIBLOC®", said Rudolf Widmann, AOP's CEO. "Amomed has the focus on cardiology and intensive care medicine required to successfully introduce this product."
"We are eager to make the availability of RAPIBLOC® known to our hospital customers," said Günther Kneissl-Mayer, Amomed's General Manager. "With RAPIBLOC® Amomed gains access to its 2nd originator product after EMPRESSIN® (the only licensed Vasopressin for treatment of septic shock in Europe to date). This will strongly support Amomed in establishing its role as a leading player in the field of intensive care medicine in Europe. We believe that the unique features of RAPIBLOC® will prompt physicians to reconsider the value of ultra-short acting beta-blocker therapy as the therapy of choice, when a critical situation requires a highly predictable and precisely controllable sympatholytic intervention."
RAPIBLOC® (Landiolol) 20 mg/2 ml concentrate solution for injection, and powder for solution for infusion in two strengths (300 mg / 600 mg) have recently been approved in a decentralized procedure involving most European countries.
About AOP Orphan Pharmaceuticals AG
For further information, please visit: http://www.aoporphan.com
For more information, please visit: http://www.amomed.com/en
Austrian Compliance Award 2017 vergeben